Palatin Technologies Inc. is a biopharmaceutical company dedicated to developing innovative, first-in-class therapeutics for diseases with significant unmet medical needs. The company's core scientific focus revolves around the melanocortin receptor system, a family of G protein-coupled receptors involved in a wide range of physiological functions, including sexual function, inflammation, and ocular diseases. Palatin's flagship product is Vyleesi (bremelanotide injection), approved by the U.S. Food and Drug Administration (FDA) for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Beyond Vyleesi, Palatin maintains an active research and development pipeline, exploring other melanocortin receptor agonists for various indications. These include programs targeting inflammatory and autoimmune diseases, such as dry eye disease and uveitis, as well as other ophthalmologic conditions. The company aims to leverage its expertise in melanocortin chemistry to bring novel therapeutic options to patients worldwide.
We couldn't find any ticker for PTN. Please check if the ticker was entered correctly—or if it is listed. If not, we don't have any data for that asset at the moment :(
...and much more!